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Cancer cellsTransient Receptor Potential (TRP) channel proteins are a diverse family of proteins that are expressed in many
organisms, tissues and cell types. TRP channels respond to a variety of stimuli, including light, mechanical or
chemical stimuli, temperature, pH or osmolarity. In addition, several TRP family members have been identiﬁed
as downstream molecules in the G protein-coupled receptor signaling pathway. TRP proteins are involved in a
variety of cell functions both in non-excitable and excitable cells due to their diverse permeability to cations
and their ability to modulate intracellular Ca2+ signaling. Emerging evidence suggests that TRP channel dysfunc-
tion signiﬁcantly contributes to the physiopathology of a number of diseases, including cardiovascular, neurolog-
ical, metabolic or neoplastic disorders. This review focuses on the implication of TRP proteins in the pathogenesis
of some of themost prevalent disorders in human. We summarize the current ﬁndings regarding the role of TRP
proteins in the development of cardiovascular disease, diabetes mellitus as well as diabetic complications, and
tumorigenesis and present TRP proteins as targets of potential diagnostic and therapeutic strategies.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Transient receptor potential (TRP) channels are a family of ion chan-
nels distantly related to voltage-gated superfamilies. TRP channels are
expressed in a variety of organisms such yeasts, worms, ﬂies and mam-
mals, including human, where they play important cellular functions.
TRP proteins were initially identiﬁed in Drosophila, where a spontane-
ously occurring mutation of the trp and trpl genes selectively abolish
the delayed, light-sensitive and sustained depolarization due to Na+
and Ca2+ inﬂux in the photoreceptors [1]. As a consequence, the TRP
Drosophila mutant showed a transient rather than sustained light-
sensitive depolarization and receptor potential, which designated the
name to these channels [2].
The metazoan TRP family has been subdivided into seven major
groups: three major subfamilies closely related to Drosophila TRP
(TRPC (canonical), TRPV (vanilloid), TRPA (ankyrin) and TRPM
(melastatin)), two subfamilies that are more distantly related to TRP
(TRPP (polycystin) and TRPML (mucolipin)), and a less related TRPN
group (also known as NOMPC (no mechanoreceptor potential C) that
has not been found in mammals but is expressed in ﬂies and worms,
and cold-blooded vertebrates (see [3,4]. In addition yeast and other
fungi have been reported to express a TRP channel subfamily known
TRPY (yeast) [4]. TRP proteins form ion channels mostly non-selectiveUniversity of Extremadura, Av.
00; fax: +34 927257110.for monovalent and divalent cations, with some exceptions such as
TRPM4 and TRPM5, which, unlike other TRPmembers, show a great se-
lectivity for monovalent cations, and TRPV5 and TRPV6 that are highly
selective for Ca2+.
TRP channels have been shown to be gated by a variety of physical
and chemical stimuli, including stretch, changes in temperature and a
large number of endogenous (such as diacylglycerol or Ca2+) or exoge-
nous ligands. Some of them have also been reported to be activated by
intracellular Ca2+-store depletion [5,6].
Accumulating evidence have demonstrated that TRP channels play
important roles both in physiological as well as pathophysiological pro-
cesses. TRP channels function as receptor-operated, second-messenger
operated or store-operated channels facilitating the inﬂux of Na+ and
Ca2+, which, in turn, contributes to membrane depolarization and the
activation of Ca2+-dependent mechanisms in a variety of systems and
organs [7]. Furthermore, dysregulation of TRP channel function, which
might include abnormal expression levels, cellular location or muta-
tions, has been found associated to a large number of disorders, thus re-
vealing the crucial biological relevance of these channels. In the present
review we have focused on three of the most prevalent pathologies:
cardiovascular disorders, diabetes mellitus and cancer, and their associ-
ation with TRP channel dysfunction.
2. TRP channels in the cardiovascular system
Nearly all TRP channels (TRPs) are expressed in both excitable and
non-excitable cells of the cardiovascular system (for reviews covering
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been detected functionally by current recordings or by molecular biolo-
gy techniques as RT-PCR, western blotting or immunostaining. TRPs can
open upon direct ligand binding, G-protein coupled signalling, and
membrane depolarization. Actually, they can sense a variety of different
stimuli including pressure, oxidative stress, sheer stress, mechanical
stretch, lipids, hypertrophic signals and inﬂammation products. TRPs
are involved in several fundamental cardiovascular cell functions, as
they integrate multiple stimuli and transduce their activity to down-
streamcellular signal pathways generally via Ca2+ entry andmembrane
depolarization. Thereby, TRPs play a crucial role in smooth muscle and
cardiac myocytes contraction, relaxation, proliferation, differentiation,
and cell death.
2.1. Role of TRP channels in the vascular system
Vascular smoothmuscle cells (VSMCs) play a central role in control-
ling vascular tone and maintaining the integrity of vessel wall. Several
reports have shown that TRP channels-mediated Ca2+ entry plays an
important role in the regulation of vascular tone, mechano-sensing, an-
giogenesis, cell proliferation, and various vascular disorders [11–13].
2.1.1. Vascular tone regulation
Most of TRPs are expressed in blood vessels, especially in endothelial
cells and vascular smooth muscle cells and they contribute to vascular
tone regulation and myogenic response. Within TRP channels TRPC
family is likely the mediator of receptor activation and the induced
vascular constriction [11,12]. Indeed, TRPC1 has been suggested to con-
tribute to store operated Ca2+ entry (SOCE) induced by endothelin-1
(ET-1) in caudal arteries [14]. Conversely, overexpression of TRPC1 in
rat pulmonary artery enhanced SOCE-mediated vasoconstriction [15].
However, TRPC1 gene disruption did not attenuated aortic smoothmus-
cle vasoconstriction [16,17]. Other agonists such as angiotensin II also
stimulated both TRPC1 and TRPC6 in mesenteric artery [18]. Mean-
while, ET-1 also activated TRPC7 and TRPC3 in rabbit coronary artery
[19]. TRPC6 was also implicated in α1-adrenergic receptor-induced
Ca2+ entry [20] and in vasopressin-responses in A7R5 cells [21]. More-
over, the elimination of TRPC6 prevented acute hypoxic pulmonary va-
soconstriction in TRPC6-null mice [22]. However and unexpectedly,
TRPC6-KO mice exhibited elevated blood pressure and enhanced
agonist-induced contractility in isolated tracheal [23], aortic rings and
cerebral arteries [24], although these effects have been related to
TRPC3, which is up-regulated in TRPC6-deﬁcient mice [24].
Moreover, TRPs are also involved in myogenic responses and in
stretch-activated channels (SAC), which respond to mechanical stress
as well as cell swelling [25]. Independent studies have shown that
TRPC6 or TRPM4 downregulation attenuated signiﬁcantly the
pressure-induced arterial smooth muscle depolarization and myogenic
vasoconstriction of intact cerebral artery [26,27]. Nevertheless, genetic
ablation of either trpc6 or trpm4 genes has little effect on the pressure-
induced constriction of mice cerebral arteries [24,28]. Therefore, further
investigation is required to resolve both channels role in mechano-
sensitivity and myogenic tone regulation. Alternatively, two other TRP
proteins, the polycystic kidney disease associated TRPP1 and TRPP2
also known as PKD1 and PKD2, were proposed as regulators of SAC in
VSMCs [29]. Indeed, themesentericmyogenic tonewas signiﬁcantly im-
paired in TRPP1-null mice, meanwhile the deletion of TRPP2 in TRPP1-
deﬁcient mice restored SAC activity and myogenic tone [29].
2.1.2. VSMC growth and vascular remodelling
During vascular development, wound repair, and inﬂammatory
occlusive diseases such as atherosclerosis and post-angioplastic reste-
nosis, VSMCs undergo rapid phenotypic switching from the “differenti-
ated” or “contractile” state to the highly “migratory” and “proliferative”
state, [12]. VSMCs switch from a “contractile” to a “synthetic” prolifera-
tive phenotype is regulated by a rise in [Ca2+]i, which activates Ca2+-dependent factors of transcription [30]. Several TRPs seems implicated
in [Ca2+]i enhancement during VSMCs proliferation and vascular re-
modelling [12]. Studies from our laboratory showed that TRPC1 associ-
ates with Orai1 upon agonist stimulation and their protein levels were
signiﬁcantly increased in synthetic aortic VSMCs compared to quiescent
cells [31]. We showed that the increase in SOCE in synthetic VSMCswas
inhibited either by TRPC1 or Orai1 protein knockdown.We also demon-
strated that protein knockdown of TRPC1 or Orai1 inhibited SOCE acti-
vation of transcription factor, P-CREB, and further VSMCs proliferation
[31]. Kumar and colleagues also have shown that phenotypic switching
of VSMCs caused an up-regulation of TRPC1 levels accompanied with
enhanced Ca2+ entry and proliferation, and TRPC1 speciﬁc antibody
blocked all these effects [32]. Others studies have shown that TRPC1 is
up-regulated in proliferative human coronary VSMCs [33] and rat
aorta [34]. Interestingly, TRPC3 and TRPC6 over-expression was ob-
served in patients with idiopathic pulmonary arterial hypertension
that is characterised by proliferation of pulmonary artery smooth mus-
cle cells (PASMCs) [35]. Other studies demonstrated that TRPC6 is up-
regulated in PASMCs treated with PDGF and ET-1 [15], meanwhile the
TRPC3 blocker, Pyr3, inhibited VSMC proliferation and prevented
stent-induced arterial remodelling [36], although it should be noted
here that Pyr3 also might block Orai channels [37]. Furthermore, others
TRPs such as TRPV1 and TRPV4 are up-regulated by hypoxia [38], and
are involved in migration of PASMCs [39]. Beside, TRPM3 is expressed
in both contractile and proliferative VSMCs [40], and Mg2+ inﬂux
through TRPM7 stimulated VSMCs growth and differentiation [41].
To summarize, evidences suggesting functional importance of TRPCs
in the vasculature are considerable and TRPs role in vessel reactivity and
especially in VSMCs proliferationmake them an attractive potential tar-
gets for therapeutic strategies to improve vascular disorders and related
pathologies [42].
2.2. Overview of the role of TRP channels in cardiac disorders
The heart is a pump that beatsmore than 100,000 times daily, due to
an electrical conduction system, which connects the sinoatrial (SA)
node to cardiac myocytes via specialized muscle ﬁbres as the bundle
of His, and the ﬁbres of Purkinje. While TRPs physiological role still re-
mains under debate, considerable advances have been made in deter-
mining their contribution to cardiomyopathies, cardiac ﬁbrosis,
cardiac remodelling, etc. [10,13,43]. In this review we will focus on the
role of TRPs in cardiac hypertrophy and in cardiac conduction disorders.
2.2.1. Role in arrhythmogenesis
TRPM4 and several TRPCs are present in SA node cells and some of
them are thought that interact with the Cav1.2 channel to regulate car-
diac pacemaking, conduction, and ventricular contractility during
cardiogenesis [44]. However, it is unclearwhether any of these channels
is involved in the cation conductance that regulates the pacemaker
activity. Recently, the involvement of TRPM4 in cardiac conduction
anomalies has been well documented [45]. Several TRPM4 mutations
were detected in family with cardiac conduction disorders, including
progressive familial heart block type I [46], isolated cardiac conduction
diseases [47] and atrioventricular block and right bundle branch block
in patientswith Brugada syndrome [48].Most of thesemutations result-
ed in an increase of TRPM4 expression and in current density, which
disturb apparently cardiac conduction by prolonging membrane depo-
larization. On the other hand, others TRPs seem involved in arrhythmia
such as TRPM7 and TRPC3 that are signiﬁcantly up-regulated in human
atrial ﬁbroblasts from patients with atrial ﬁbrillation [49,50] and TRPC3
or TRPA1 which regulate heart rate [26].
2.2.2. Cardiac hypertrophy
Cardiac hypertrophy develops in response to increased pressure or
mechanical overload due to cardiac diseases such as valvular stenosis
or hypertension. Its well known that the calcineurin-NFAT complex is
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cardiac hypertrophy (see [51]); and a role for TRPC channels and
the calcineurin-NFAT complex has been conﬁrmed in several studies
(as reviewed in [10,52,53]). Stimulation with agonists such as
endothelin-1, phenylephrine and angiotensin that induce hypertrophy
upregulated TRPC1 TRPC3, and TRPC7 [10]. In this way, TRPC1-
deﬁcient mice failed to develop cardiac hypertrophy in response to
pressure overload and neuroendocrine stimulation [54]. Meanwhile,
overexpression of TRPC3 in mouse cardiac myocytes promoted store-
operated Ca2+ entry stimulation of calcineurin-NFAT signalling, which
secondarily stimulated cardiac hypertrophy [55]. Another report has
shown that TRPC6 are upregulated in failing human hearts and in also
mouse hearts in response to activated calcineurin-NFAT pathway acti-
vated by pressure overload [56]. Conversely, TRPC6 knockdown
prevented Angiotensin–II inducedNFAT activation andhypertrophic re-
sponses in rat cardiomyocytes [57]. Interestingly, cardiac myocytes
transfection with dominant negative constructs of TRPC3, TRPC6, or
TRPC4, showed reduced hypertrophic responses induced either by neu-
roendocrine agonist infusion or pressure overload stimulation through
calcineurin/NFAT activation [51,53]. Others TRPs such as TRPV1,
TRPV2, PKD1 and PKD2 seem also involved in heart hypertrophy [10].
Indeed, TRPV1 knockdown protected mice heart from ischemic injury
and also from pressure overload induced cardiac hypertrophy [58].
Furthermore, cardiac myocytes isolated form PKD2 null mice displayed
a sever alteration in intracellular Ca2+ concentration handling, which
has been also related to heart hypertrophy observed in patientswith au-
tosomal dominant polycystic kidney disease [59].
Taken together, severalﬁndings usingdifferent approaches in animal
model suggest that TRPs, either TRPC1/3/4/6/7, TRPV1/2, or PKD1/2, are
important mediators of pathological hypertrophy and may serve as po-
tential therapeutic targets [9].
3. Involvement of TRP channels in the pathogenesis of
diabetes mellitus
3.1. Expression and functional role of TRP channels in β-cells
The secretion of insulin by the pancreatic β cell is a complex process
driven by changes in membrane potential and [Ca2+]i. Brieﬂy, when
glucose enters the β cell, via the GLUT-2 transporter, the metabolism
of glucose produces ATP, which closes ATP-sensitive K+ channels. Con-
sequently, the membrane potential depolarizes, which, in turn, results
in the activation of voltage-dependent Ca2+ channels. The subsequent
rise in [Ca2+]i, together with the resulting Ca2+-induced Ca2+ release,
leads to the exocytosis of insulin-containing vesicles [60,61]. The
model of glucose-induced insulin secretion is based on membrane de-
polarization upon closure of the ATP-dependent K+ channels; however,
this phenomenon requires the existence of an inward current that
drives the membrane potential to more positive values. The nature of
this background current, which might be due to Cl- efﬂux or cation in-
ﬂux, remains unknown [62], but TRP channels have been presented as
candidates for this depolarizing current [63,64].
A variety of TRP channels have been described both in primary β-
cells or insulin-secreting cell lines, including TRPC1, TRPC2, TRPC3,
TRPC4, TRPC5, TRPC6, TRPM2, TRPM3, TRPM4, TRPM5, TRPV1, TRPV2,
TRPV4 and TRPA1 [63,65–67]. Most of these isoforms are expressed in
insulinoma cell lines derived from mouse (MIN6 and βTC3) or rat
(INS-1). But alsomany of them have also been described in primary tis-
sue, including the expression of TRPC1, TRPC2, TRPC3, TRPV2, TRPV4,
TRPM2 and TRPM3 reported in mouse islets, TRPC1, TRPC4, TRPM2
and TRPV1 in rat islets, and TRPM2, TRPM4 and TRPM5 expressed in
human islets (for a review see [63,65]).
Despite several TRPC familymembers have been described in prima-
ry and culture insulin-secreting cells, the role of TRPC channels in insu-
lin secretion remains uncertain. Early studies suggested that TRPC
channels mediate the uncharacterized depolarizing current thataccount for the Ca2+-release activated cation current in ETC3 cells
[68]. The analysis of blood glucose concentration in TRPC4-deﬁcient
and wild type mice did not reveal differences at basal glucose levels
under fasting conditions or following intraperitoneal glucose adminis-
tration [69]. A more recent study has revealed that Ca2+ entry through
TRPC4 channel activation is essential for leptin-induced AMPK activa-
tion, which in turn promotes ATP-sensitive K+ channels trafﬁcking to
theplasmamembrane, thus providing evidence for a role of TRPC4 in in-
sulin release in rat INS-1 and primary pancreatic β-cells [70].
The role of TRPM channels has been more extensively investigated
in insulin-secreting cells. Knock-out of TRPM5 has been reported to at-
tenuate [71] or abolish [72] glucose-induced insulin release. The
TRPM5-mediated current is of a small magnitude (~20 pA at -80 mV
at maximal stimulation); therefore, this channel is able to inﬂuence
electrical activity, regulating fast [Ca2+]i oscillations, during glucose
stimulation, when ATP-sensitive K+ channels are closed and conse-
quently there is a high electrical resistance [61,65,71]. Glucose has
been reported to activate TRPM5 by differentmechanisms that includes
rises in [Ca2+]i [73], changes inmembrane potential [73] or cytosolic ar-
achidonic acid concentration [74] and even as a result of the direct acti-
vation of the sweet taste receptors T1R2/T1R3, which have also been
reported to be expressed in pancreatic β-cells [75]. TRPM5, in addition
to TRPM4, have also been involved in the regulation of insulin release
due to the actions of neurotransmitter, such as acetylcholine, during
the cephalic and enteric phases of secretion, a mechanism involving a
distinct [Ca2+]i -insulin secretion coupling [72]. Nevertheless, the role
of TRPM4 in insulin secretion evoked by glucose is uncertain. In
insulin-secreting cell lines, such as INS-1, HIT-T15, RINm5F, β-TC3,
MIN-6 and the α-cell line INR1G9 cells, inhibition of TRPM4 (i.e. by ex-
pressing a dominant negative TRPM4 construct) has been reported to
attenuate glucose-induced both Ca2+ signals and insulin release, thus
suggesting that Ca2+ entry through TRPM4 is an important component
for Ca2+ signals and insulin release [76,77]. In addition, TRPM4-
containing vesicles are translocated to the plasmamembrane upon cel-
lular stimulation, which might play a relevant role in the exocytotic
mechanism [76,77]. However, studies on TRPM4-deﬁcient mice report-
ed similar tolerance to intraperitoneal injection of glucose thatn wild
type animals and no difference in glucose-stimulated insulin secretion
from freshly isolated pancreatic islets was detected [78]. These data in-
dicate that TRPM4 might not be required for the signal mechanism fol-
lowing glucose stimulation.
TRPM2 has been described as a cation-permeable channel activated
by H2O2 in the insulinoma cell line CRI-G1 [79]. In addition to its role in
β-cell apoptosis, TRPM2 has been suggested to contribute to insulin se-
cretion induced by glucose in siRNA TRPM2-treated mouse pancreatic
islets [80] and TRPM2-deﬁcient mice [81], due to a reduced increases
in [Ca2+]i, thus suggesting that TRPM2 contributes to Ca2+ signals dur-
ing glucose stimulation. In addition to the conduction of Ca2+ inﬂux in
β-cells, TRPM2 has also been found localized in the lysosomes and
might be involved in lysosomal Ca2+ release, thus participating in mul-
timodal signaling elements regulating Ca2+ mobilization in β-cells
through membrane depolarization, Ca2+ inﬂux, and release of Ca2+
from intracellular stores [82].
The role of TRPV channels in insulin secretion is uncertain. TRPV1
channels have been reported in some nerve ﬁbers of mouse islets [83]
but not in human islets [65]. TRPV2 has been found in mouse MIN6 en
culture β-cells, where this channel is translocated from the cytoplasm
to the plasma membrane in response to insulin. Insulin-induced trans-
location of TRPV2 to the plasma membrane has been reported to be
stimulated by glucose as a positive feed-back mechanism [84]. Finally,
TRPV4 has been described as a cationic channel activated by a diversity
of physical stimuli, including volume changes, osmolality or stretch [85].
It has been hypothesized that volume changes inβ-cells induced by glu-
cose stimulationmight induce the activation of TRPV4 channels in these
cells, thus contributing to the [Ca2+]i changes observed in response to
hypotonicity and volume increase [86].
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cells, where treatment with 4-hydroxy-2-nonenal, allylisothiocyanate,
H2O2,methylglioxal and 15-deoxy-[increment]12,14-prostaglandin J2 re-
sult in a dose-dependent increase in [Ca2+]i and insulin release [67,87],
which suggests that TRPA1 might represent the link between inﬂamma-
tory signals, oxidative metabolism and insulin secretion.
3.2. Overview of the involvement of TRP channels in the pathophysiology of
type 2 diabetes mellitus
3.2.1. Role TRP channels in the pathogenesis of type 2 diabetes mellitus
Diabetes mellitus (DM) groups several metabolic chronic disorders
characterized by hyperglycemia and abnormal carbohydrate, protein,
and fat metabolism. It is caused by the absence of insulin secretion by
the pancreatic β-cells, or due to defects in insulin uptake in the periph-
eral tissue. DM is broadly classiﬁed under two categories, which include
type 1 and type 2 diabetes.Whereas, type 1 DM is caused by an autoim-
mune destruction of the β-cells leading to a lack of insulin production,
type 2 DM occurs as a combination of reduced amount of insulin pro-
duction from pancreatic β-cells and peripheral insulin resistance [88].
Although the analysis of the role of TRP channels in the pathogenesis
of DM deserves further studies, the current data suggest a possible link
between TRP and type 2 DM. Type 2 DM is a polygenic disease involving
a genetically determined susceptibility to β-cells dysfunction. This sus-
ceptibility includes abnormalities in genes encoding ion channels or in
those that regulate ion channel function, membrane targeting or ex-
pression, whichmight lead to impairment of the β-cell electrical chang-
es and, consequently, reduced insulin secretion [61,89]. Since TRP
channels have been suggested to play a role in the excitation-
secretion coupling in β-cells, functional modiﬁcations of TRP channels
might play a role in the pathophysiology of type 2 DM. In this regard,
a study reported nine TRPM5 single nucleotide polymorphisms that
might be associated with prediabetic phenotypes in subjects at in-
creased risk for type 2 diabetes, including insulin insensitivity,
hyperglycaemia and low glucagon-like peptide-1 levels during oral glu-
cose tolerance test [90].
A more recent study has reported that TRPM8, expressed in primary
sensory neurons innervating internal tissues, might act as a regulator of
serum insulin. TRPM8-deﬁcient mice respond normally to glucose ad-
ministration but show increased rates of insulin clearance compared
with wild-type animals and increased expression of insulin-degrading
enzyme in the liver [91].
Babes et al. have revealed that the anti-diabetic drug glibenclamide
is an activator of TRPA1 channels, providing evidence for some adverse
effects observed in diabetic patients treated with this drug. This study
also reports that both inhibition of ATP-sensitive K+ channels and
activation of TRPA1might explain the initial exacerbation of hyperinsu-
linism in glibenclamide-treated type 2 diabetic patients and the pro-
gressive deterioration of β-cell function [92].
3.2.2. TRP channels in the complications associated to type 2 diabetes
mellitus
3.2.2.1. Role of TRP channels in diabetic vasculopathy. Diabetes mellitus is
associated to dysfunction of both vascular endothelial and smoothmus-
cle cells, the latter involving impaired relaxation or enhanced contrac-
tile response to agonists, which contributes to vascular complications
[93]. The involvement of TRP proteins in vascular dysfunction is contro-
versial with studies providing opposite results depending on the cell
type investigated. In the saphenous vein from type 2 diabetic patients,
TRPC1 and TRPC6 protein expression is signiﬁcantly decreased,
although their mRNA levels remained unchanged [94]. In contrast, in
the caudal artery smoothmuscle cells fromGoto-Kakizaki rats, a diabet-
ic model that shows a signiﬁcantly lower systolic blood pressure as
compared to control Wistar rats, the expression of TRPC1, TRPC4 and
TRPC6 is signiﬁcantly increased [95].TRPC proteins abnormalities have also been suggested to contribute
to the endothelial dysfunction associated to diabetes mellitus. Bishara
et al have demonstrated that TRPC1 is overexpressed in bovine aortic
endothelial cells upon chronic exposure to high glucose concentration,
which results in enhanced Ca2+ entry in these cells. Although the link
between the enhanced Ca2+ entry and endothelial dysfunction has
not been completely established, this study suggest a potential role of
TRPC1 in this process [96].
3.2.2.2. Role of TRP channels in platelet hyperactivity associated to type 2
diabetes mellitus.While the pathophysiology of types 1 and 2 DM is dif-
ferent, most of the complications are similar, which may include
macrovascular and microvascular complications. Platelets from type 2
diabetic patients exhibit enhanced activity, which contributes to the de-
velopment of micro- and macroangiopathy [97,98]. Platelets from dia-
betic subjects show altered Ca2+ homeostasis, including reduced Ca2+
extrusion and enhanced Ca2+ release from intracellular stores and in-
ﬂux, leading to both increased resting [Ca2+]i and response to agonists
[99]. We have reported several differences in the expression of Ca2+-
permeable channels in platelets from diabetic donors as compared to
healthy individuals, including enhanced expression of Orai1 and
TRPC3, together with a reduced expression of TRPC6 in diabetic subjects
[100]. Treatment of platelets from healthy humans with high glucose
has been reported to increase surface expression of TRPC6 in a time-
and concentration-dependent manner, and by a phosphatidylinositol
3-kinase-dependent pathway, which is accompanied by an increased
non-capacitative Ca2+ entry [101]. Furthermore, platelets from dia-
betics patients show an enhanced endogenous production of reactive
oxygen species, resulting in enhanced activity of the Bruton's tyrosine
kinase or proteins of the Src family of kinases [102], which have been
shown to be required for platelet Ca2+ entry and function [103,104].
The increased Ca2+ inﬂux in response to agonists in platelets from
type 2 diabetes has been attributed to different abnormalities. First of
all, the Na+/Ca2+ exchanger operates in reversemode, thus introducing
Ca2+ into the cell, which contributes to the enhanced Ca2+ entry ob-
served in response to thrombin [105]. In addition, the non-
capacitative Ca2+ entry pathway is increased in cells from diabetic sub-
jects [106]. On the other hand, under conditions that avoid autocrine
platelet activation and using Mn2+ as a surrogate for Ca2+ entry, to
avoid interference with Ca2+ extrusion via active pumping by the
PMCA or Na+/Ca2+ exchange, we have found that in platelets from
type 2 diabetics SOCE is selectively reduced, probably due to impair-
ment of the association of TRPC1 and TRPC6 with STIM1 and Orai1
[106], two key components of SOCE in human platelets [107,108]. Nev-
ertheless, even though SOCE is attenuated in these cells, the overall
Ca2+ inﬂux stimulated by agonists is signiﬁcantly increase in platelets
from type 2 diabetic patients, which contributes to platelet
hyperaggregability and hyperactivity, which supports the role of TRPC
proteins as potential therapeutic targets for the treatment of diabetic
complications.
3.2.2.3. TRP channels in diabetic nephropathy. Diabetic nephropathy,
a process characterized by nephrotic syndrome and diffuse
glomerulosclerosis, is another diabetic complication caused by
angiopathy of capillaries in the kidney glomeruli and one of the
most prevalent disorders associated to TRP channel dysfunction.
Both, TRPC1 and TRPC6 channels have been reported to play a rele-
vant role in regulating glomerular ﬁltration by modulating the con-
tractile function of the glomerular mesangial cells; therefore,
attenuation of the expression of these channels in mesangial cells
might result in impairment of Ca2+ inﬂux and consequently, abnor-
mal glomerular hemodynamics in diabetic subjects [93]. Recent
studies have demonstrated that TRPC1 expression is reduced in dia-
betic patients [94] and diabetic db/dbmice [109]. Reduced TRPC1 ex-
pression has been found to occur in the later stages of diabetic
nephropathy [109]. The attenuation of TRPC1 expression has been
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which results in reduction of trpc1 gene expression, which might, ul-
timately, result in the development of diabetes nephropathy [110].
More recently, the role of microRNAs (miRNA) in the development
of diabetic complications has been investigated. MiRNAs are small
non-coding RNAs that act by regulating the expression of their target
genes. MiR-135a has been found to be upregulated in serum and
renal tissue from patients with diabetic nephropathy, db/db mice,
which has been associated with microalbuminuria and renal ﬁbrosis.
Upregulation of miR-135a attenuates the expression o TRPC1 and re-
duces SOCE during diabetic renal injury. Knockdown of miR-135a
was found to restore the levels of TRPC1 and reduce the synthesis
of ﬁbronectin and collagen. The role of TRPC1 in this process has
been further demonstrated by overexpression of this channel in
mesangial cells, which was able to reverse the pathological effects
of miR-135a [111].
Graham et al have reported that chronic high glucose exposure of
glomerular mesangial cells and diabetes in streptozotocin-injected rats
lead to downregulation of TRPC6 expression, which, in rats, occurs
after 2 weeks of streptozotocin administration, thus suggesting a possi-
ble contribution of TRPC6 in the early stages of diabetes [112].
In human mesangial cells, downregulation of TRPC6 induced by
chronic high glucose exposure has been attributed to enhancement of
NADPH oxidase activity and/or expression level that increases endoge-
nous reactive oxygen species, which, in turn, activate PKCα. Activation
of PKCα downregulates either directly or indirectly TRPC6 expression
in these cells [113]. Overproduction of reactive oxygen species is a char-
acteristic pathological process in diabetes mellitus, that has also been
observed in cultured cells chronically exposed to high glucose; there-
fore, oxidative stress has been suggested as a general mechanism for
diabetes-associated TRPC protein dysregulation [93].
3.2.2.4. TRP channels in diabetes associated erectile dysfunction. Erectile
dysfunction is a common alteration associated to diabetes whose path-
ogenesis might involve TRP channels. Analysis of the expression of dif-
ferent channels in the corpus smooth muscle cells from diabetic
humans and rats revealed the presence of TRPC1, TRPC3, TRPC4 and
TRPC6 with a higher expression level of TRPC4 in rats as compared to
controls. Down-regulation of TRPC4by in vivo gene transfer of dominant
negative TRPC4 into the smooth muscle of the corpus cavernosum re-
stored erectile function in streptozotozin-induced diabetic rats, and
similar results were obtained by gene transfer of dominant negative
TRPC6 [114], thus suggesting a relevant role for TRPC4 in the develop-
ment of erectile dysfunction associated to diabetes mellitus [115].
Finally, severalmembers of the TRPC, TRPMandTRPV subfamilies, as
well as TRPA1 have been associated to the development of diabetic neu-
ropathic pain as a result of dysregulation of intracellular Ca2+ homeo-
stasis and the generation of reactive oxygen species [116,117].
4. TRP channels and tumorigenesis
TRP channels are known to respond to a diverse collection of
chemical and physical stimuli, such as temperature or mechanical
stress, reﬂected in their common presence in sensory neurons
[118]. However, due to Ca2+ permeability of many of TRP channels,
they often ﬁnd themselves involved in the regulation of calcium ho-
meostasis and the associated cellular processes [119]. TRP channels
are known to play an inﬂuential role in the cell cycle, often by regu-
lating gene transcription, as well as inﬂuencing other cellular pro-
cesses such as proliferation, apoptosis or cellular motility [120].
Often, variations in expression of TRP channels are associated with
changes in intracellular Ca2+ and alteration of proliferative path-
ways, promoting or inhibiting apoptosis in affected cells [119,121,
122]. These properties of TRP channels naturally draw attention to
them as to likely regulators of various mechanisms of cellular
development.4.1. Cancer and calcium homeostasis
Changes in the cell cycle that lead to cancer typically shift the bal-
ance towards enhanced proliferation,while simultaneously suppressing
pathways leading to cell death [121]. Commonly, the disturbances in af-
fectedmolecular pathways involve alterations in [Ca2+]i homeostasis in
cells. Pathways initiating apoptosis frequently involve alterations in cal-
cium homeostasis through cytoplasmic, ER-mediated or mitochondrial
mechanisms [123,124], while pro-proliferatory pathways often involve
Ca2+ entry via the plasma membrane (PM) expressed ion channels
[121,122,125]. On the other hand, the established tumor cell lines, as
well as freshly transformed cells often lose sensitivity to calcium signals
as well as the need for the external Ca2+ for proliferation and survival
[126,127].
It should be noted that the observed patterns of intracellular calcium
release suggest functional presence of ion channels not only in the PM,
but also in a number of subcellularmembranes, such as endoplasmic re-
ticulum (ER), where they provide pathways for Ca2+ passage from var-
ious organelles [120]. The classical examples of such ion channels
include the inositol 1,4,5-trisphosphate receptor and ryanodine recep-
tor channels, that have been known for some time to be localized to
the ER and to participate in regulation of apoptosis, [128,129]. However
recent studies point at the intracellular localization of more and more
ion channels [130] includingﬁrst few examples belonging to the TRP su-
perfamily, such as TRPM2, TRPM8 [131,132].
The principal Ca2+-dependent pathways, affected by TRP channel
activity and regulating the cell cycle, include pathways mediated by a
calcium/calmodulin-dependent kinase II (CaMKII), which plays an im-
portant role in Ca2+-calmodulin regulated calcium reuptake as well as
T-cell selection and activation [133–135] and a nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB), a protein complex
controlling transcription of DNA in response to various harmful stimuli
[136,137]. Other important calcium-dependent factors regulating the
cell cycle include calcium-dependent cysteine proteases, calpains and
the calcium-dependent serine-threonine phosphatase calcineurin
forming a combined calpain-calcineurin signalling complex [138] sensi-
tive to local [Ca2+] and modulating the expression of interleukins
which, in turn, stimulate cellular growth and differentiation [139].
Next, in this section, we discuss the involvement of the TRP channels
in the tumorigenesis, grouping themby their principal effect on the pro-
gression on various types of cancer.
4.2. Inﬂuence of TRP
4.2.1. Pro-proliferative role of TRPs
The TRP channels known to enhance the proliferation of the trans-
formed cells appear to be relatively uniformly distributed among the
three subfamilies harboring the cell-fate affecting players: TRPC, TRPM
and TRPV. We start our short overview with TRPV6, the ion channel
playing principally pro-proliferative role and for which the most data
has been accumulated.
Unlike the majority of the TRPV family proteins, which show clear
voltage and temperature dependence and often serve as sensors in cen-
tral and peripheral nervous systems [140], TRPV6 is not associated with
known sensory function. The channel is known to have a Ca2+ selectiv-
ity greater than typical for TRPs; however it does not exhibit a typical
single-channel behavior [141], which may explain the absence of the
sensory function. Instead Ca2+ entry via this channel is modulated via
changes to its expression induced by estrogen, progesterone, tamoxifen
and vitamin D, affecting proliferation and survival of cancer cells [142,
143]. The channel is known to be naturally present in the epithelial
cells of kidney, intestine, placenta and pancreas, with its expression
being elevated upon malignant transformation in carcinomas of colon,
thyroid gland, ovary and breast as well as chronic myelogenous leukae-
mia cell [143–149]. The channel is also known to play an important role
in the prostate cancer progression,with its very low expression levels in
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the development of metastases [145,148]. In these phases of cancer
the TRPV6 expressionwas shown to be inhibited by dihydrotestosteron,
- an androgen receptor agonist and stimulated by becalutamide, - an an-
drogen receptor antagonist [145,146,150]. Interestingly, its transloca-
tion to the PM has been shown to be mediated by Orai1 - the ion
channel responsible for SOCE [151].
Another member of the TRPV family, the TRPV2 channel has been
shown to be important for the growth and invasive properties of pros-
tate tumors [152] while its stimulation in glioblastoma cells made the
malignant tissues more sensitive to cytotoxic chemotherapeutic agents
[153]. A preliminary indication of possible expression level changes of
TRPV5 together with TRPV6 was reported in non-small-cell lung cancer
[154]; however further characterization is necessary to conﬁrm this.
The studies of the TRPC family involvement in carcinogenesis have
originally been concentrated on the TRPC1 channel, which has been im-
plicated in regulation of cell fate and motility [155–158]. Interestingly,
the role that TRPC1 plays was shown to be different, depending on the
stage of cancer considered. While in normal tissues TRPC1 promoted
cell proliferation, in tumour tissues the presence of protein tended to
shift balance towards apoptosis [8]. The channel is also known to be im-
plicated in the regulation of the motility of the nasopharyngeal carcino-
ma and cell lung carcinoma cells, human malignant gliomas [159–161].
These observations concentrating on the TRPC1 have recently been ex-
panded by the observations that TRPC5 and 6 also play important roles
in the advancement of carcinogenesis although in alternative ways, due
to belonging to different TRPC subgroups and exerting differential ef-
fects on physiological factors [162]. Thus, TRPC6modulates the progres-
sion of gastric cancer via regulation of G(2)/M phase transition [163],
and is associated with proliferation of several types of cancer cells, in-
cluding prostate cancer LNCaP [164] and human hepatoma cells [165],
while TRPC5 is essential for induction of a P-glycoprotein pump, that
is overproduced in cancer cells leading to a suppression of anticancer
drug resistance [166].Furthermore, TRPC3 and, mainly, TRPC6 have
been found to be overexpressed in breast cancer epithelial cells and
breast cancer biopsy tissues [167,168]. In addition, TRPC6 is, with
TRPC1, TRPM7, TRPM8, and TRPV6, among the channels overexpressed
in human breast ductal adenocarcinoma. While TRPC1, TRPM7 and
TRPM8 expression has been reported to correlate with proliferative pa-
rameters, TRPV6 has been found to be mainly overexpressed in the in-
vasive breast cancer cells [169]. Altogether, these ﬁndings present TRP
channels as candidate targets for breast cancer diagnosis and therapy.
Similarly to TRPC and TRPV subfamilies, the TRPM family contains
multiple members having pro-proliferative effect in transformed cells,
TRPM4, 5 and 7. Initial evidence of TRPM4 and TRPM5 involvement in
cancer was limited to observations of alterations in their expression
levels in CD5+ B-cell lymphomas andWilms tumours and rhabdomyo-
sarcomas (Beckwith-Wiedemann syndrome) respectively [170,171].
Later, changes in the expression level of TRPM4were found to be impor-
tant for the proliferation of the prostate cancer cells in the androgen-
independent phase and cervical cancer-derived HeLa cells [172–174].
However the majority of evidence in the TRPM family concentrates on
the TRPM7 channel, which is implicated in enhancing proliferative po-
tential of the grade III breast tumour cells [175] as well as participating
in gastric and pancreatic cancers [176–178], human hypopharyngeal
squamous cell and nasopharyngeal carcinomas [179,180], prostate
cancer [181] and enhances invasive properties of neuroblastoma
[182–184].
4.2.2. Pro-apoptotic role of TRPs
Similarly to the TRP channels having a pro-proliferative effect on
transformed cells, the pro-apoptotic players are uniformly distributed
among the TRP subfamilies. The TRPC and TRPV subfamilies are repre-
sented by only one channel each: TRPC3 and TRPV1, and TRPM1 and 2
represent the TRPM subfamily. Starting with the TRPC3 channel, its ex-
pressionwas shown to be elevated by a prolonged Ca2+ store depletion,affecting alpha-adrenergic stimulation and anti-apoptotic signaling in
various prostate cancer cells [185,186]. Stimulation of its expression or
activity was also shown to enhance apoptosis in rat cardiomyocytes or
to attenuate tumor proliferation and migration in MCF-7 breast cancer
cells [187]. Interestingly, in ovarian cancer cells activation of TRPC3 ac-
tually enhances cell proliferation and contributes to this type of cancer
[188]. The second single protein subfamily representative, the TRPV1
channel, is shown to change its expression levels during the tumorigen-
esis in prostate, colon, bladder and pancreas cancers [189–192]. The
channel is known to induce apoptosis following its stimulation by
vanilloids in prostate and colorectal cancers [193,194].
Talking about the ﬁrst representative of the TRPM subfamily, the
TRPM1 channel, it is necessary to note that, similarly to TRPV6, the
channel does not exhibit a common single-channel type of gating and
instead is considered to be a leak channel modulated by Go protein in
response to activation of the mGluR6 receptor, which brings about a
complete closure of the channel [195,196]. Similarly to TRPC1, TRPM1
channel exhibits a complex pattern of expression that depends on the
stage of the cancer. It is found in human melanoma cells at high levels
in benign tissues with its levels decreasing in primary melanomas and
no appreciable amounts in metastatic tissues [190,197,198]. These
changes in the expression levels are reportedly controlled by
microphthalmia transcription factor in a way dependent on the state
of cellular differentiation [199,200] and these changes in the level of
TRPM1 expression are suggested to control apoptosis induction at dif-
ferent stages of cancer [197,201]. Interestingly, the microRNA miR-211
that is localized to intron 6 of the Trpm1 gene shows the same pattern
of expression andwas recently shown to affect epithelial ovarian cancer
as well as melanoma by arresting cells in the G0/G1-phase, inhibit pro-
liferation and induce apoptosis [202,203]. Additionally, a short isoform
of the chanel (TRPM1-S) is known to exist and control the trafﬁcking
of the full-length TRPM1 to the plasma membrane [204,205].
The secondmember of the TRPM family covered in this subsection is
the TRPM2 channel, known to react to TNF-α or oxidative stresswith its
activation leading to decreased viability and increased apoptosis of the
immune cells [206]. Additionally its overexpression or increased activity
and the associated increases in Ca2+ inﬂux have been shown to contrib-
ute to apoptosis induction in rat insulinoma RIN-5 F and in U937mono-
cyte cells, and lysosomal calcium release was shown to contribute to
apoptosis induction in the rat β pancreatic cell line INS-1 [82,207]. Sim-
ilarly, inhibition of histone deacetylase upregulated TRPM2 and induced
apoptosis in T24 bladder cancer cells[208]. Interestingly, in prostate,
TRPM2 changes its localization from near-PM to nuclei with its knock-
down inhibiting the growth of the cancerous but not that of the normal
cells [131]. Similarly to TRPM1, TRPM2 has a short isoform that, when
combined with the full length protein, exhibits a strong dominant-
negative effect. Co-expression of this isoform in HEK293 cells overex-
pressing full length TRPM2 suppressed Ca2+ entry and protected cells
from death, conﬁrming the role of the channel in cell survival [209].
4.2.3. Migration
Many of the TRP channels that were already mentioned to play pro-
proliferatory or pro-apoptotic roles have also been shown to affect the
motility of the transformed cells. Thus, recent studies position TRPM7
as a part of mechanosensory complex driving metastasis formation
and invasiveness of breast cancer cells, in amanner involving the kinase
domain of the channel and phosphorylation of Src and MAPK but not
AKT kinases [210–213]. In breast cancer cells expression of TRPM7
channel was shown to regulate EGF-induced STAT3 phosphorylation
and expression of the marker of epithelial-mesenchymal transition
vimentin [214].
Another member of the TRPM subfamily involved in the regulation
of motility of the transformed cells is TRPM8 channel. It was initially
found to be present at high levels in prostate tissues [215] with its ex-
pression levels varyingduring the progression of theprostate cancer fol-
lowing a complex pattern: increasing in the cancerous tissues, however
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tate cancer [216,217]. The channel has recently been shown to be in-
volved in the regulation of motility and tumorigenesis of multiple
cancer types, such as oral squamous carcinoma, pancreatic ductal ade-
nocarcinoma cells and lung cancer [218–220]. In prostate cancer cells
the modulatory effect of TRPM8 on motility of prostate tumors was
known even longer, with recent reports starting to shed light on the
speciﬁc mechanisms that implicate newly identiﬁed TRP channel-
associated factors (TCAFs) as proteins regulating TRPM8 activity and
its trafﬁcking to plasma membrane [221,222].
The TRPV2 channel was also shown to stimulate migration of the
PC3 prostate cancer cells while being activated by endogenous
lysophospholipids [223]. On the pro-apoptotic side, the principal evi-
dence elucidating role of the involved channels in regulating cellular
motility lies primarily with the presence of TRPM1 negatively correlat-
ing with metastasis formation [197,201]. These observations, while
still scarce, seems to point at a universal pattern of pro-proliferatory
channels also having a stimulatory effect on cell motility, and pro-
apoptotic players having a tendency to inhibit motility.Transparency document
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